Parenteral Dosage Forms for Clinical Studies

The Master IDIQ for Parenteral Dosage Forms for Clinical Studies, awarded by the National Cancer Institute's Development Therapeutics Program, focuses on developing and producing pharmaceutically acceptable parenteral dosage forms for promising cancer treatment agents. The contract enables the production of small to intermediate-sized batches of injectable pharmaceutical products intended for Phase I and II clinical trials. These dosage forms are specifically designed to support cancer research by providing researchers with precisely manufactured injectable medications for investigational studies.

The task orders under this IDIQ appear to be initial kick-off activities, each valued at $1,000 and completed by November 29, 2013. The contract is designated as a Partial Small Business set-aside, suggesting opportunities for smaller pharmaceutical development and manufacturing firms. The contract vehicle supports batch productions ranging from 100-200 units for initial studies to 1,000-5,000 units for more advanced clinical trials. While the specific prime contractors are not detailed in the provided documentation, the contract is structured to support multiple contractors in developing parenteral drug formulations for cancer research. The National Cancer Institute's Division of Cancer Treatment and Diagnosis serves as the primary funding and oversight agency for these pharmaceutical development efforts.